1-Amino-1-propyl-3,3,5,5-tetramethylcyclohexane | 219810-67-0

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: 1-Amino-1-propyl-3,3,5,5-tetramethylcyclohexane
• 英文别名: MZR 601；1-propyl-3,3,5,5-tetramethylcyclohexylamine；3,3,5,5-Tetramethyl-1-propylcyclohexan-1-amine
• CAS: 219810-67-0
• 化学式: C₁₃H₂₇N
• 分子量: 197.364
• InChiKey: OMYKWZGACJRFAJ-UHFFFAOYSA-N

物化性质

• 沸点：
  230.3±8.0 °C(Predicted)
• 密度：
  0.810±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  3,3,5,5-四甲基环己酮 在 lithium aluminium tetrahydride 、 三(2-氯乙基)胺 、 四氯化钛 作用下， 以 乙醚 、 氯仿 为溶剂， 反应 30.0h， 生成 1-Amino-1-propyl-3,3,5,5-tetramethylcyclohexane
  参考文献：
  名称：

  Synthesis and structure–affinity relationships of 1,3,5-alkylsubstituted cyclohexylamines binding at NMDA receptor PCP site

  摘要：

  A series of 1,3,5-alkylsubstituted cyclohexylamines 2 were synthesized as ligands for the N-methyl-D-aspartate (NMDA) receptor phencyclidine (PCP) binding site. Pure diastereomers with defined configuration of amino group 2-ax and 2-eq were obtained. The optimal size of 1,3,5-substituents was determined for cyclohexylamines 2 with an equatorial amino group in the lowest energy conformation using Hansch analysis. According to the data, the lipophilic part of cyclohexylamines 2 does not discriminate between hydrophobic regions of the PCP binding site but rather recognizes this site as a whole lipophilic pocket. (C) 2000 Editions scientifiques et medicales Elsevier SAS.

  DOI：

  10.1016/s0223-5234(00)00153-7

文献信息

• Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors
  申请人：——

  公开号：US20040087658A1

  公开（公告）日：2004-05-06

  The invention relates to a novel drug combination therapy useful in the treatment of dementia comprising administering an 1-aminocyclohexane derivative such as memantine or neramexane and an acetylcholinesterase inhibitor (AChEI) such as galantamine, tacrine, donepezil, or rivastigmine.

  该发明涉及一种新型药物组合疗法，可用于治疗痴呆，包括给予一种1-氨基环己烷衍生物，如美万特或奈拉美喜，以及一种乙酰胆碱酯酶抑制剂（AChEI），如加兰他明、他克林、多奈哌齐或利伐替明。
• NMDA receptor antagonists and their use in inhibiting abnormal hyperphosphorylation of microtubule associated protein tau
  申请人：——

  公开号：US20040019118A1

  公开（公告）日：2004-01-29

  Aminocyclohexane and aminoalkylcyclohexane compounds, which are systemic-ally-active as NMDA receptor antagonists, are effective in inhibiting abnormal hyperphosphorylation of microtubule associated protein tau, method of treating disorders resulting from or associated with abnormal hyperphosphorylation of microtubule associated protein tau, and pharmaceutical compositions comprising the same.

  氨基环己烷和氨基烷基环己烷化合物作为NMDA受体拮抗剂在系统上具有活性，对抑制微管相关蛋白tau异常过度磷酸化有效。涉及治疗由于或与微管相关蛋白tau异常过度磷酸化相关的疾病的方法，以及包含这些化合物的药物组合物。
• Treatments for flaviviridae virus infection
  申请人：Malcolm A. Bruce

  公开号：US20060198824A1

  公开（公告）日：2006-09-07

  The present invention provides methods for treating infections, in a host, by viruses belonging to the Flaviviridae family, such as HCV, comprising administering an Ara-C homologue to the host.

  本发明提供了一种治疗由属于黄病毒科(Flaviviridae)的病毒引起的感染的方法，例如丙型肝炎病毒(HCV)，包括向宿主施用Ara-C同源物。
• Novel treatment for alzheimer's disease
  申请人：EPFL Ecole Polytechnique Fédérale de Lausanne

  公开号：EP2111858A1

  公开（公告）日：2009-10-28

  The present invention concerns a new pharmaceutical composition comprising an antagonist and a co-agonist of the N-methyl-D-aspartate-type glutamate receptor (NMDAR). The inventors found that the co-administration of these two compounds effectively inhibits production of amyloide-β peptide. In patient's suffering from Alzheimer's disease, these peptides are deposited in the extracellular matrix forming neuritic "plaques". Therefore, the present inventors identified a new possibility for prophylaxis and/or treatment of Alzheimer's disease by stopping the continued formation of neuropathological extracellular deposits.

  本发明涉及一种新的药物组合物，包括N-甲基-D-天门冬氨酸型谷氨酸受体（NMDAR）的拮抗剂和共激动剂。发明人发现这两种化合物的联合使用有效地抑制了淀粉样β肽的产生。在患有阿尔茨海默病的患者中，这些肽沉积在细胞外基质中形成神经突起“斑块”。因此，本发明人发现了一种新的预防和/或治疗阿尔茨海默病的可能性，即通过阻止神经病理性细胞外沉积物的持续形成。
• METHODS OF TREATING CNS DISORDERS
  申请人：PAPADAKIS Kelly

  公开号：US20090275597A1

  公开（公告）日：2009-11-05

  The present invention relates to methods of treating various CNS disorders, e.g., mania, bipolar disorder and schizophrenia, by administering NMDA receptor antagonists, alone or in combination with dopamine receptor antagonists.

  本发明涉及治疗各种中枢神经系统疾病的方法，例如躁狂症、双相情感障碍和精神分裂症，通过单独或与多巴胺受体拮抗剂联合给予NMDA受体拮抗剂。